[ad_1]
Warnings about a high valuation for the S&P 500 are justified, but one sector has bucked the trend with a significant decline to its forward price-to-earnings ratio.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...